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Fibrolamellar carcinoma has a distinctive morphology and immunophenotype, including cytokeratin 7 and CD68
co-expression. Despite the distinct findings, accurate diagnosis of fibrolamellar carcinoma continues to be a
challenge. Recently, fibrolamellar carcinomas were found to harbor a characteristic somatic gene fusion,
DNAJB1–PRKACA. A break-apart fluorescence in situ hybridization (FISH) assay was designed to detect this
fusion event and to examine its diagnostic performance in a large, multicenter, multinational study. Cases initially
classified as fibrolamellar carcinoma based on histological features were reviewed from 124 patients. Upon
central review, 104 of the 124 cases were classified histologically as typical of fibrolamellar carcinoma, 12 cases
as ‘possible fibrolamellar carcinoma’ and 8 cases as ‘unlikely to be fibrolamellar carcinoma’. PRKACA FISH was
positive for rearrangement in 102 of 103 (99%) typical fibrolamellar carcinomas, 9 of 12 ‘possible fibrolamellar
carcinomas’ and 0 of 8 cases ‘unlikely to be fibrolamellar carcinomas’. Within the morphologically typical group
of fibrolamellar carcinomas, two tumors with unusual FISH patterns were also identified. Both cases had the
fusion gene DNAJB1–PRKACA, but one also had amplification of the fusion gene and one had heterozygous
deletion of the normal PRKACA locus. In addition, 88 conventional hepatocellular carcinomas were evaluated
with PRKACA FISH and all were negative. These findings demonstrate that FISH for the PRKACA rearrangement
is a clinically useful tool to confirm the diagnosis of fibrolamellar carcinoma, with high sensitivity and specificity.
A diagnosis of fibrolamellar carcinoma is more accurate when based on morphology plus confirmatory testing
than when based on morphology alone.
Modern Pathology (2018) 31, 141–149; doi:10.1038/modpathol.2017.103; published online 1 September 2017
Fibrolamellar carcinoma is a rare primary liver
carcinoma with distinctive clinical and morphologic
characteristics. Fibrolamellar carcinoma is not
associated with elevated serum alpha fetoprotein
levels, is enriched in younger age groups, and is not
associated with underlying liver disease. The tumor
is characterized by neoplastic cells with abundant
eosinophilic granular cytoplasm, prominent
nucleoli, and striking intratumoral fibrosis, classi-
cally arranged in parallel or lamellar bands. At the
immunohistochemical level, fibrolamellar carci-
noma is characterized by cytokeratin 71,2 and CD68
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co-expression.3 These immunostains are useful to
support the diagnosis of fibrolamellar carcinoma.
Despite the distinctive histologic and clinical features
of fibrolamellar carcinoma, misclassification is a
persistent problem, most commonly with cases of
conventional hepatocellular carcinoma incorrectly
classified as fibrolamellar carcinoma. As one example,
data from the SEER database found an average age of 39
years for fibrolamellar carcinoma,4 which is signifi-
cantly older than the average age of 27 found in
pathologically confirmed cases reported in original
studies.5 Other studies have specifically examined
primary liver tumors with abundant intratumoral
fibrosis and found that they can closely mimic
fibrolamellar carcinoma.6 These findings suggest the
need for more objective diagnostic markers for fibrola-
mellar carcinoma. Proper classification of tumors is the
foundation on which modern clinical management and
therapy is based. In this regard, the likelihood of
significant advancements in understanding the biology
of fibrolamellar carcinoma and developing novel
therapies depends in the first place on studying cases
that are actually fibrolamellar carcinomas.
Honeyman et al discovered a novel somatic
recurrent 400 kb deletion on the short arm of
chromosome 19, giving rise to an in-frame DNAJB1–
PRKACA gene fusion in fibrolamellar carcinoma.7
The resulting fusion protein is thought to constitu-
tively activate the kinase activity of protein kinase A
catalytic subunit alpha and to function as the
oncogenic driver of fibrolamellar carcinoma. There-
fore, its detection provides a robust diagnostic
biomarker. A subsequent study found the fusion
transcript in only ~80% of fibrolamellar carcinomas,
but most of the cases in this study did not undergo
central pathology review.8 Recently, a clinical test for
fibrolamellar carcinoma has been developed based on
fluorescent in situ hybridization (FISH) to detect the
PRKACA rearrangement and was positive in all of 26
cases of fibrolamellar carcinoma and in none of the
conventional hepatocellular carcinomas.9
Currently, fibrolamellar carcinoma is diagnosed in
most centers based on H&E morphology, often
supplemented with immunostains for CK7 and
CD68. In order to further validate FISH based testing
for routine clinical care, we undertook a retro-
spective multi-institutional, multinational study of
a large number of cases originally diagnosed as
fibrolamellar carcinoma based on morphology. The
primary goal of this study is to examine the
diagnostic utility of the PRKACA FISH assay by
examining a larger cohort of clinical specimens
including resections, needle biopsies, and cytology
aspirates. As part of this, in a subset of cases the
FISH test was applied to multiple sections from the
same tumor as well as to cases with primary and
metastatic disease. The second goal was to identify
fibrolamellar carcinoma cases with unusual FISH
patterns, which may provide novel biological
insights and represent interpretative challenges in
clinical diagnosis.
Materials and methods
We retrospectively retrieved cases diagnosed as
fibrolamellar carcinoma from the institutional
archives or consultation files of numerous medical
centers from around the world (Figure 1). Slides and
tissue blocks were retrieved from patients who
provided informed consent per required institutional
protocols. The study was approved by the institu-
tional review boards of the respective institutions
and in concordance with ethical guidelines of the
1975 Declaration of Helsinki.
All of the retrieved cases were centrally reviewed
simultaneously by two of the authors (RPG and MST)
blinded to clinical information, the results of
immunohistochemistry, and FISH results. The study
cases include 112 resections and 12 biopsies. The
formalin fixed paraffin embedded tissue cases were
classified based on morphology alone into typical
examples of fibrolamellar carcinoma, cases which
possibly represented fibrolamellar carcinoma, and
cases which were unlikely to be fibrolamellar
carcinoma. The criteria used for typical fibrolamellar
carcinoma included the presence of the following
morphological findings: (i) eosinophilic, monoto-
nous neoplastic cells with (ii) abundant granular
cytoplasm, (iii) open nuclear chromatin, (iv) con-
spicuous macronucleoli, and (v) dense and/or
lamellar type intratumoral fibrosis. Alcohol-fixed
smears from six cases associated with core biopsy
specimens were also reviewed (RPG and SEK).
Unstained sections from a tissue microarray com-
posed of 88 conventional hepatocellular carcinoma,
6 cases of fatty liver disease, and 7 examples of
normal liver (SR, TL, and PS) along with unstained
sections from a tissue microarray with eight fibrola-
mellar carcinomas (VA) were obtained for FISH.
Immunohistochemistry for CK7 (clone OV-TL;
Dako) and CD68 (clone KP1; Dako) were performed
at the Mayo Clinic on unstained slides of full tissue
sections from each of the cases diagnosed as
fibrolamellar carcinoma.10 FISH was performed and
interpreted using a previously published break-apart
probe set for the PRKACA locus.9 Because fusion
genes in cancer often have multiple partners, we
used a break-apart probe strategy for the FISH. In this
assay, a green and a red probe target adjacent
sequences of DNA. The green probe binds to the
PRKACA gene while the red probe binds adjacent
and will be lost regardless of the fusion partner.
Because the two probes are adjacent in normal liver
tissue, two yellow signals are seen in cells without
the deletion, one for each chromosome. However,
the 400 kb deletion seen in fibrolamellar carcinoma
results in loss of the DNA covered by the red probe.
Thus, a positive result is typically a separate green
signal, (loss of a single red signal) with a solitary
intact yellow fusion signal, per tumor nucleus. To be
considered positive, the abnormal signal pattern had
to be present in greater than 50% of the tumor cells.
This cutoff was empirically determined using
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examples of normal liver tissue, of which no
example ever had more than 5% of cell nuclei had
any abnormal pattern.
After histologic review, immunohistochemistry,
and FISH results, patient ages at diagnosis and
history of background liver disease were reviewed.
To investigate further one of the cases with
amplification of the FISH probes, quantitative PCR
(qPCR) for PRKACA exon 8 and 9 (encoding the kinase
domain) was performed on four randomly selected
fibrolamellar carcinomas, a single randomly selected
cholangiocarcinoma, and a single case of fibrolamellar
carcinoma with an unusual FISH result. This assay
measures total PRKACA RNA and does not specifically
identify the fusion transcript. Total RNA was extracted
from formalin fixed paraffin embedded tissues using
miRNeasy FFPE Kit (Qiagen, CA) and was treated with
DNase I (Life Technologies). RNA concentration was
measured by Qubit 2.0 Fluorometer (Thermo Fisher
Scientific, MA). cDNA was synthesized with random
hexamers and 1μg of total RNA using the iScript
cDNA Synthesis kit (Bio-Rad, CA). qPCR was per-
formed on a LightCycler 480instrument (Roche, Basel,
Switzerland) with 96-well plates. Human Universal
Reference cDNA (Takara Bio, CA) was used as the
calibrator. Hydrolysis probe UPL # 6 (Roche, Basel,
Switzerland) and PCR primer set (PRKACA-qPCR-F, 5′-
TTTGCCACAACTGACTGGAT-3′; PRKACA-qPCR-R,
5′-CCAGGGCCTTTAAACTTTGG-3′) were used to
amplify a 77 bp amplicon of PRKACA mRNA. Hydro-
lysis probe UPL # 69 (Roche, Basel, Switzerland) and
PCR primer set (PGK1-qPCR-F, 5′-GGAGAACCTCC
GCTTTCAT-3′; PGK1-qPCR-R, 5′-GCTGGCTCGGCTT
TAACC-3′) were used to amplify a 78 bp amplicon of
the reference PGK1 mRNA. Each 20 μl qPCR assay
included 1×BiolineSensiFAST Probe No-ROX Mix
(Bioline, MA), 6 uM of each primer, and 3 uM of probe
and 5.0 μl of diluted cDNA. qPCR conditions are as
follows: incubation at 95 °C for 4min followed by 45
cycles of 95 °C for 10 s and 60 °C for 50 s. Relative
expression ratios were calculated using the Calibrator
Normalized Relative Quantification Method (Roche,
Basel, Switzerland). qPCR for the PRKACA target gene
and the reference PGK1 gene were carried out in
triplicate wells, respectively.
Finally, tumor DNA from a single fibrolamellar
carcinoma case with atypical FISH results was
evaluated with a SNP array (OncoScan, Affymetrix)
following the vendor provided instructions.
Results
We gathered cases from 124 patients that were
diagnosed as fibrolamellar carcinoma. In 17 of these
Figure 1 Fibrolamellar carcinoma origins—The geographic origin of the cases of fibrolamellar carcinoma included in this study.
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cases, there were 2 or 3 additional samples available
from a single patient for analysis, including 6 cases
with alcohol-fixed cytology preparations and paired
formalin fixed paraffin embedded tissue sections. In
the 17 cases with multiple samples, each of the
samples from separate time points or the same
procedure showed concordant results. Forty-two
(34%) cases were from the Mayo Clinic in Rochester
or the consultations files of the senior author (MST).
Various clinical and biological aspects were pre-
viously published, including FISH results, on
twenty-eight cases from the Mayo Clinic, Cleveland
Clinic, and the University Hospital of Basel.9–11
Based solely on morphology, the tumors were
classified at central review as histologically typical
of fibrolamellar carcinoma in 104 (84%) cases. In 12
(10%) cases, the histology was classified as possible
fibrolamellar carcinoma and in 8 (6%) cases the
tumor was classified as unlikely to be fibrolamellar
carcinoma. The results are discussed below using the
central review histological classification of typical,
possible, or unlikely to be fibrolamellar carcinoma.
Typical Fibrolamellar Carcinoma
Patient ages were available in 85 of 104 (82%) cases.
The average was 23.8±7.8 years for patients with
tumors classified as typical fibrolamellar carcinoma.
The cases showed the characteristic morphology of
fibrolamellar carcinoma. In four cases, the tumors
showed areas of solid growth without intratumoral
fibrosis. However, typical areas were present else-
where in these cases. Each of the 6 cytology specimens
was classified as typical for fibrolamellar carcinoma.
Immunohistochemistry was performed in 92 of
104 typical fibrolamellar carcinoma cases. Cytoker-
atin 7 was diffusely positive in 87 cases (95%),
patchy in 2 cases (2%), focally expressed in 2 cases
(2%), and negative in a single case (1%). CD68 was
diffusely positive in 83 (90%) cases, patchy in 2
Figure 2 Typical fibrolamellar carcinoma results. (a) Typical fibrolamellar carcinoma. The neoplastic cells are characterized by abundant
eosinophilic cytoplasm, nuclei with open chromatin, and prominent nucleoli. The tumor cells form trabecula which are separated by
bands of fibrosis. (b) Cytokeratin 7 is positive in the tumor cells. (c) A CD68 immunostain shows characteristic cytoplasmic staining. (d)
PRKACA break apart FISH in a typical fibrolamellar carcinoma. The FISH result is positive. The tumor cells show separate green signals
and intact yellow signals (due to overlapping red and green signals).
Modern Pathology (2018) 31, 141–149
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(2%), weak in 5 (5%), and negative in 2 (2%) cases.
In 1 case, CK7 and CD68 were both negative. The
negative staining cases all had questionable staining
quality, showing a lack of staining of the internal
controls (bile ducts for CK7, Kupffer cells/macro-
phages for CD68) or were very small biopsies with
limited tissue (1 case).
PRKACA FISH was successful in all but 1 case
(n=103 of 104). PRKACA was rearranged in 102 of
103 cases tested. The areas with sheet like growth
(seen in four cases) showed the same FISH pattern as
areas with the classical growth pattern. FISH was
successful in 4 of 6 alcohol-fixed cytology prepara-
tions, with two cases failing to hybridize. Each of the
4 alcohol-fixed cytology specimens were positive for
PRKACA rearrangement. Figure 2 shows an example
of typical fibrolamellar carcinoma, its immunophe-
notype and PRKACA FISH result. The most common
rearrangement pattern showed a separate green
signal with an intact yellow signal per nucleus,
followed by two green signals and two intact yellow
signals per nucleus. These patterns were seen in 100
of 102 (98%) cases. In the remaining two cases there
were unusual signal patterns that were still consis-
tent with PRKACA rearrangement, but also showed
additional FISH abnormalities.
In the first case with unusual FISH results, there
were 410 separate green signals per nucleus, with
only 1 or 2 intact yellow signals per nucleus, a finding
seen in ~30% of the tumor nuclei (Figure 3). These
results suggest amplification of the rearranged
PRKACA locus. Follow-up qPCR confirmed a 2–5-
fold increase in PRKACA mRNA in this case,
compared to 4 randomly selected fibrolamellar carci-
noma cases with typical FISH patterns (Figure 3).
The second unusual FISH rearrangement pattern
showed separate single red and single green signals
per nucleus, without an intact yellow signal. We
performed RT-PCR for DNAJB1–PRKACA with two
different primer sets and confirmed the presence of
the DNAJB1–PRKACA fusion transcript (Figure 4).
We then followed up with a SNP array and identified
a 10MB heterozygous deletion which encompassed
the hybridization site for the green probe of the
PRKACA probe set (Figure 4). Taken together, these
data are consistent with deletion of the intact
PRKACA locus on one allele of chromosome 19,
with formation of the DNAJB1–PRKACA fusion gene
on the other allele.
The single typical fibrolamellar carcinoma without
a PRKACA rearrangement by FISH affected a 14-
year-old girl with a family history of the Carney
Complex.12
Possible Fibrolamellar Carcinoma
Cases were classified histologically as possible
fibrolamellar carcinoma when they showed some
but not all of the typical features of fibrolamellar
carcinoma (Figure 5). Immunohistochemistry
showed diffuse CK 7 staining in 7/12 cases, patchy
staining in 2/12 cases and no staining in 3/12 cases.
CD68 was expressed in 11 cases and negative in a
single case. The CD68-negative case was cytokeratin
7 positive. FISH was successful in all 12 cases and
was positive for PRKACA rearrangement in 9 cases,
of which 8 showed the typical co-expression of
cytokeratin 7 and CD68, while the last case was
cytokeratin 7 positive but CD68 negative. In each of
the 9 cases where PRKACA was rearranged, the FISH
signal pattern was characteristic (1 green and 1
yellow signal per nucleus). The three FISH negative
cases were re-classified as not fibrolamellar
carcinoma.
Unlikely Fibrolamellar Carcinoma
The cases classified as unlikely to be fibrolamellar
carcinoma had some morphological features to
suggest a diagnosis of fibrolamellar carcinoma but
also had findings that made the diagnosis less likely,
such as significant nuclear pleomorphism or the lack
of distinct macronucleoli or abundant eosinophilic
cytoplasmic (Figure 6). Immunohistochemistry was
completed on 7 of 8 cases classified as ‘unlikely
fibrolamellar carcinoma’. Cytokeratin 7 was diffusely
positive in 3 cases, patchy in 2 others, and negative
in the remaining 2 cases. CD68 was positive in 1 case
and negative in the other 6 cases. One case showed
cytokeratin 7 (patchy) and CD68 co-expression. FISH
for PRKACA rearrangement was negative in all cases,
showing two intact PRKACA loci (Figure 6).
All of the cases classified as unlikely to be
fibrolamellar carcinoma based on central H&E
review were finally classified as conventional hepa-
tocellular carcinoma. Clinical data were available for
7 of these cases. The ages at resection ranged from 47
to 72 years, with a median of 61 years. Two of these
individuals had histories of chronic hepatitis B. One
case had portal fibrosis in the background liver,
while two had cirrhosis.
Figure 3 Fibrolamellar carcinoma with PRKACA locus amplifica-
tion. (a) PRKACA break Apart FISH results are consistent with
amplification of the PRKACA locus. The fibrolamellar carcinoma
showed typical morphology. There are greater than 10 separate
green signals per tumor cell nucleus with fewer intact yellow
signals. (b) Quantitative reverse transcription-PCR shows a 2–5-
fold increase in PRKACA mRNA compared to four randomly
selected fibrolamellar carcinomas (FL-HCC-2-5) and one randomly
selected cholangiocarcinoma (CLC).
Modern Pathology (2018) 31, 141–149
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Tissue Microarrays
On the first tissue microarray, all of the 88 conven-
tional hepatocellular carcinomas were negative for
PRKACA rearrangements, as were samples of non-
neoplastic liver that were either normal (N=7) or
showed fatty change (N=6). Each of the eight (100%)
fibrolamellar carcinomas in the second tissue micro-
array was positive for PRKACA rearrangement in the
typical pattern. These eight cases were not included
in the calculations done in this study because whole-
slide sections were not reviewed, but serve as a
positive control for the tissue microarrays of
conventional hepatocellular carcinoma, ensuring
that the FISH assay works well on microarray
samples.
Discussion
The results from this study demonstrate the utility of
FISH as a clinical test to detect the DNAJB1–
PRKACA that is found in fibrolamellar carcinomas.
The FISH test is highly sensitive and specific, as
shown in this multicenter study of over 100 cases
from North America, South America, and Europe.
Additional tests that can confirm a diagnosis of
fibrolamellar carcinoma are important. While the
morphological findings are distinctive, there can be
overlap with conventional hepatocellular carcino-
mas, as demonstrated by the results of this study,
where 9% of cases submitted as fibrolamellar
carcinomas could not be confirmed, a problem that
is also extensively discussed in review articles.5,13,14
As a result of this problem, many published studies
of fibrolamellar carcinoma appear to include tumors
that are most likely not fibrolamellar carcinomas, but
rather other types of hepatocellular carcinoma. This
outcome is suboptimal, as advances in understand-
ing the biology and potential therapies for fibrola-
mellar carcinoma are most likely to occur when
studies exclusively examine fibrolamellar carcino-
mas. Attempts to address this problem began with
the report of overexpression of anterior gradient-2
protein as a marker of fibrolamellar carcinoma15 and
continued with studies showing the utility of CD68
Figure 4 Fibrolamellar carcinoma with uncommon FISH results (a) PRKACA break-apart FISH shows separate red and green signals in a
morphologically typical fibrolamellar carcinoma. This FISH signal pattern raised the possibility of either a different fusion partner for
PRKACA or heterozygous loss of the PRKACA locus without involvement in a gene fusion event. (b). Array comparative genomic
hybridization data at chromosome 19p demonstrated heterozygous loss of the PRKACA locus due to a 10 Mb deletion (orange bidirectional
arrow) including the hybridization site of the FISH probe (shown in green).
Figure 5 Possible fibrolamellar carcinoma. An example of a case
classified as a ‘possible fibrolamellar carcinoma’ based on
morphology, characterized by intratumoral fibrosis and neoplastic
cells with granular cytoplasm. The cytoplasm of the tumor cells is
amphophilic in nature. This case was positive for PRKACA break-
apart by FISH testing.
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and cytokeratin 7 co-expression in confirming a
histological diagnosis of fibrolamellar carcinoma.3
While immunostains for CK7 and CD68 are widely
available and easy to use, the CD68 stain in
particular can fail in some cases for technical
reasons. The seminal discovery of the DNAJB1–
PRKACA fusion7 has permitted the development of
the next generation of testing.9 This molecular based
testing is robust and has the advantage of identifying
the defining genetic lesion of this tumor. We propose
that the diagnosis of fibrolamellar carcinoma should
now be based on (1) compatible morphology and (2)
confirmatory testing, with preference for molecular
testing. When molecular testing is not available,
co-expression of CK7 and CD68 would be an
acceptable alternative. This approach is well in line
with the generally accepted method for defining
hepatocellular carcinoma morphological subtypes.16
A strict definition will also better serve patients
when enrolling in clinical trials for the treatment of
fibrolamellar carcinoma. The use of confirmatory
testing does not impugn the diagnostic skills of
pathologists, who still need to identify cases needing
testing based on morphology, but instead reflects the
well documented need for confirmatory testing to
ensure correct diagnosis. This approach allows
patients an early benefit from the molecular revolu-
tion and will hopefully lay the foundation for future
advances.
The data in this study shows that the detection of
PRKACA rearrangement has a sensitivity of 99% for
the diagnosis of fibrolamellar carcinoma. The test
performs well on biopsies and can even be extended
to alcohol-fixed cytology specimens.
All but one case of typical fibrolamellar carcinoma
was positive for PRKACA rearrangement. The diag-
nosis for this case was confirmed by the combination
of characteristic morphology and characteristic
immunohistochemistry for cytokeratin 7 and CD68.
While neither morphology nor immunohistochemis-
try are infallible, in this case, their combined use in
experienced hands provides strong support for the
diagnosis. The clinical information (age, absence of
background liver disease, family history of the
Carney complex in first degree relative) and the
current genetic model for fibrolamellar carcinoma
are all in keeping with that diagnosis for this case.
This case affected a 14-year-old female with a history
of the Carney complex in her mother.12 The Carney
complex is characterized by germ line PRKAR1A
mutations in the majority of patients.17 The model of
fibrolamellar carcinogenesis as a tumor driven by
activation of protein kinase A would be fulfilled in
this patient’s case by loss of PRKAR1A function,
which encodes a negative regulator of protein kinase
A activity. The combination of a germ line hit and a
second somatic hit would allow for over activity of
the catalytic subunit PRKACA. This hypothesis of
course requires confirmation.
The results from this study significantly extend the
number of non-fibrolamellar carcinoma cases tested
for DNAJB1–PRKACA fusion (N=88). All of these
cases were negative for the DNAJB1–PRKACA
fusion. In addition, two other studies have evaluated
a combined 87 cases of non-fibrolamellar hepatocel-
lular neoplasms for DNAJB1–PRKACA9,18 and all
were negative. These finding together (N=175 total
cases) indicate that the DNAJB1–PRKACA fusion is
highly specific for fibrolamellar carcinoma.
The results from this study also show that the
DNAJB1–PRKACA fusion is consistently detected in
multiple samples of different tumors (primary,
metastases) from the same patient. In addition, the
fusion is present throughout any given tumor, even
when there are varied growth patterns, including
areas of solid growth that lack the striking intramural
Figure 6 Unlikely fibrolamellar carcinoma An example of a case classified as ‘unlikely to be fibrolamellar carcinoma’ based on
morphology. (a) The tumor shows more nuclear pleomorphism than is seen in typical fibrolamellar carcinomas. (b) The growth patterns
shows pseudoacinar areas with cholestasis. This case was negative for PRKACA break-apart by FISH testing.
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fibrosis, areas that have sometimes led to classifica-
tion of such cases as mixed hepatocellular carcinoma
and fibrolamellar carcinoma. All of these findings
support the concept that the DNAJB1–PRKACA
fusion gene is an early and primary driver of
fibrolamellar carcinoma and suggests caution in
interpreting regional morphological heterogeneity
as evidence for a mixed tumor.
We also identified two unusual FISH patterns.
These patterns are important because they extend
our understanding of the genetic lesions in the
PRKACA locus and because they potentially could
represent an interpretative challenge in clinical
care. The first pattern is consistent with a
DNAJB1–PRKACA fusion gene followed by amplifi-
cation of this locus, a model which is supported by
follow-up qPCR studies. The clinical significance of
this finding is unclear because of its rarity, but the
tumor was otherwise typical for fibrolamellar carci-
noma morphologically and immunohistochemically.
The presence of amplification of a fusion gene has
been noted in other translocation-associated
tumors.19–22 Collection and study of additional
fibrolamellar carcinomas with amplification of the
DNAJB1–PRKACA fusion will be needed to deter-
mine the significance of this finding. The second
unusual pattern resulted from two genetic events; (i)
formation of the fusion gene and (ii) loss of the
PRKACA locus on the uninvolved allele. The
available data does not indicate whether the addi-
tional genetic findings in these two cases occurred at
the same time of the genetic insult leading to the
DNAJB1–PRKACA fusion, or whether these two
cases indicate additional genetic instability in this
region.
In conclusion, PRKACA FISH is a powerful tool to
confirm the diagnosis of fibrolamellar carcinoma. It
provides direct visualization of the key genomic
event in fibrolamellar carcinomas and is useful in
challenging cases. The FISH assay is highly specific
in the context of primary hepatic neoplasia. We
propose the best approach for the diagnosis of
fibrolamellar carcinoma is based on compatible
morphology with either molecular confirmation, or
if not available, then confirmation by CK7 and CD68
immunohistochemistry.
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